1Division
of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton,
Surrey, United Kingdom; 2Cancer Therapeutics Unit, The Institute
of Cancer Research, Sutton, Surrey, United Kingdom
With the development of more targeted therapeutics to treat malignant bone disease has come the associated challenge of developing more clinically relevant pre-clinical models, and identifying new non-invasive techniques capable of assessing the tumour phenotype and treatment response. To this end, a mouse model of castrate-resistant, prostate bone metastasis, propagated by direct intraosseous injection of cells, and its response to cabozantinib, has been investigated by quantitative imaging methods.